比瓦利鲁丁与肝素在有或没有救助GPI使用的患者中:从BRIGHT-4试验中预先指定的子组分析
Jia Liao1,2, Miaohan Qiu1, Xiaojian Feng3
1State Key Laboratory of Frigid Zone Cardiovascular Disease, Department of Cardiology, General Hospital of Northern Theater Command, Cardiovascular Research Institute, Shenyang, 110016, China.
BMC medicine
|September 28, 2024
概括
比瓦利鲁丁显著减少了ST升高心肌梗塞患者的死亡和出血,这些患者接受了没有糖蛋白IIb/IIIa抑制剂的初级PCI. 然而,当需要救助GPI时,好处不那么明显.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 关于ST升高心肌梗塞 (STEMI) 患者接受初级皮肤穿冠状动脉干预 (PCI) 的比瓦利鲁丁与赫巴林抗凝剂存在相互矛盾的数据.
- 糖蛋白IIb/IIIa抑制剂 (GPI) 可能会混对比疗效研究.
- BRIGHT-4试验旨在澄清这些结果.
研究的目的:
- 为了比较比瓦利鲁丁与PCI后高剂量输液的安全性和有效性,与在接受初级PCI的STEMI患者中对肝素单一治疗进行比较.
- 评估救助GPI使用对这些结果的影响.
主要方法:
- 一项涉及6016名STEMI患者的BRIGHT-4试验的亚组分析,这些患者随机获得了比瓦利鲁丁或肝素.
- 患者接受了与PCI后输液或氨酸单一治疗一起的比瓦利鲁丁.
- 糖蛋白IIb/IIIa抑制剂被保留用于救助治疗.
主要成果:
- 救助GPI使用增加了主要结局 (综合死亡或BARC 3-5出血) 和所有原因死亡的风险.
- 在不需要GPI的患者中,比瓦利鲁丁与肝素相比,主要结局,全因死亡和BARC 3-5出血的发生率明显较低.
- 在需要救助GPI的患者中,在比瓦利鲁丁和肝素之间没有观察到显著的结果差异.
结论:
- 在接受初级PCI而没有使用GPI的STEMI患者中,与肝素相比,PCI后输注的比瓦利鲁丁显著减少了死亡和严重出血.
- 由于血栓性并发症而需要救助GPI的患者,比瓦利鲁丁的益处可能会减少.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
636
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
636
Venous Thrombosis III: Interprofessional Care
3
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
3
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
483
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
483
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
3
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
3
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
155
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
155


